242 related articles for article (PubMed ID: 19272293)
21. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
22. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
[TBL] [Abstract][Full Text] [Related]
23. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
24. Discontinuation of rivastigmine in routine clinical practice.
Frankfort SV; Appels BA; de Boer A; Tulner LR; van Campen JP; Koks CH; Beijnen JH
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1167-71. PubMed ID: 16315150
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
Dhillon S
Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
27. Long-term rivastigmine treatment in a routine clinical setting.
Minthon L; Wallin AK; Eriksson S; Wattmo C; Andreasen N
Acta Neurol Scand; 2009 Mar; 119(3):180-5. PubMed ID: 18759798
[TBL] [Abstract][Full Text] [Related]
28. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
31. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
Burian R
MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
[No Abstract] [Full Text] [Related]
32. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
Cummings J; Winblad B
Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
[TBL] [Abstract][Full Text] [Related]
33. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Lee JH; Sevigny J
Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
[TBL] [Abstract][Full Text] [Related]
34. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
Muhlack S; Przuntek H; Müller T
Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
[TBL] [Abstract][Full Text] [Related]
35. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
[TBL] [Abstract][Full Text] [Related]
37. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
38. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Reñé R; Ricart J; Hernández B;
Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
[TBL] [Abstract][Full Text] [Related]
39. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
[TBL] [Abstract][Full Text] [Related]
40. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Greenspoon J; Herrmann N; Adam DN
CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]